Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring health care information both rapidly and directly to the consumer or healthcare provider. CEO, Ray Akers, features some of company's proprietary testing products, including diabetes complication and lung cancer diagnostics. Growth is derived from global strategic partnerships and distributors like Cardinal Health, Thermo Fisher and Medline. AKER is now trading for more than cash and Akers believes is it a great value and time for investors to look at the company due to rapid sales trends and product commercialization. Jill Malandrino reports from the NASDAQ Market Site in New York.

More from Video

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Elon Musk's Twitter Tirade Is the Dumbest Thing on Wall Street

Elon Musk's Twitter Tirade Is the Dumbest Thing on Wall Street

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home